coin-img-ETHETH-1.31%coin-img-BTCBTC+0.07%coin-img-SOLSOL-1.54%coin-img-USDCUSDC+0.01%coin-img-UBOXUBOX+1,953.33%coin-img-XRPXRP+0.47%coin-img-TRXTRX+0.77%coin-img-HYPEHYPE-1.52%coin-img-ETHETH-1.31%coin-img-BTCBTC+0.07%coin-img-SOLSOL-1.54%coin-img-USDCUSDC+0.01%coin-img-UBOXUBOX+1,953.33%coin-img-XRPXRP+0.47%coin-img-TRXTRX+0.77%coin-img-HYPEHYPE-1.52%coin-img-ETHETH-1.31%coin-img-BTCBTC+0.07%coin-img-SOLSOL-1.54%coin-img-USDCUSDC+0.01%coin-img-UBOXUBOX+1,953.33%coin-img-XRPXRP+0.47%coin-img-TRXTRX+0.77%coin-img-HYPEHYPE-1.52%coin-img-ETHETH-1.31%coin-img-BTCBTC+0.07%coin-img-SOLSOL-1.54%coin-img-USDCUSDC+0.01%coin-img-UBOXUBOX+1,953.33%coin-img-XRPXRP+0.47%coin-img-TRXTRX+0.77%coin-img-HYPEHYPE-1.52%
user-avatar
scanx.trade

Jagsonpal Pharmaceuticals lifts Q1FY27 PAT 22.2% to ₹132 million as margins widen

AI Market Summary
Jagsonpal Pharmaceuticals reported strong Q1FY27 results, with PAT up 22.2% and EBITDA margin expanding to 23.2% as expense growth lagged revenue, indicating operating leverage. Management cited improved medical representative productivity and core brand momentum, alongside disciplined capital allocation despite a buyback and an acquisition that expands institutional reach. The update is company-specific and unlikely to shift broader market risk appetite.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.56%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Jagsonpal Pharmaceuticals reported results for the June 2026 quarter (Q1FY27), with standalone net profit up 22.2% year on year to ₹132 million. Revenue rose 8.8% to ₹822 million, while EBITDA increased 21.4% to ₹191 million as the EBITDA margin expanded to 23.2% from 20.8%. The company attributed the performance to higher medical representative productivity and stronger sales in core brands, and said it outpaced the Indian pharma industry’s 11.6% average growth. The stock trades in India under the symbol ONUS.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.